Natural Treatment of Polycystic Ovary Syndrome

Home » fertilPEDIA » Natural Treatment of Polycystic Ovary Syndrome

By



Attention: You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.

This content is WordProof timestamped

Natural Treatment of Polycystic Ovary Syndrome

Main article: Treatment of Polycystic Ovary Syndrome Overview

Updated: 18-October-2024

Natural Treatment of Polycystic Ovary Syndrome

Doctors often recommend treating PCOS naturally first if they believe there is room for improvement. This strategy also helps later on if conventional treatment (i.e. medication) is still required.

Natural treatment options for women with PCOS include:

  • Exercise
  • Diet
  • Losing weight
  • Reduce stress
  • Environmental
  • Supplements

The actual treatment plan will depend greatly on any findings during initial examination and blood tests. Similarly, follow up blood tests and examination are also necessary to monitor (and adjust) the treatment plan.

Exercise

Exercise and being active is very important for women with PCOS. Early PCOS studies reported a link between physical inactivity, sedentary lifestyle and PCOS.1,2,3

Subsequent lifestyle modification studies reported a significant decrease in PCOS symptom severity which could reduce the need for medication or dosage levels for some women.4 Hence lifestyle modification (i.e. diet and exercise) is usually the first treatment option doctors recommend to women with PCOS.5

However exercise is reported to be more effective than diet at improving insulin levels.6 Exercise also decreases oxidative stress and inflammation, which directly improves ovary function and hormone levels.7,8

Among the various types of exercise, high-intensity interval training (HIIT) has the greatest impact on PCOS when compared to continuous aerobic exercise training (CAET), moderate-intensity continuous training (MICT) or resistance training.9,10 In one study, Benham et al. reported that HIIT significantly improved lipid profile (LDL, HDL, cholesterol) more than CAET, even though the reduction in BMI and waist circumference was similar.11 In a larger study, HIIT significantly improved sex hormone-binding globulin (SHBG), free androgen index (FAI), insulin sensitivity and menstrual cycles compared to MICT among overweight women with PCOS.12

HIIT also has a positive and long-lasting effect on anxiety and depression levels in women with PCOS.

Source: Santos I K, et al. (2022)

Significantly, Lionett et al. reported that the effect of HIIT is somewhat impaired in women with PCOS, suggesting metabolic inflexibility and a need for medication during lifestyle modification to maximise the effect of HIIT.13

Lastly, research also suggests that supervised exercise is more effective than self-regulated exercise long term (> 3 months) if that is a viable option.14

References

  1. Moran L J, et al. (2013). The contribution of diet, physical activity and sedentary behaviour to body mass index in women with and without polycystic ovary syndrome. https://academic.oup.com/humrep/article/28/8/2276/661780 ↩︎
  2. Eleftheriadou M, et al. (2012). Exercise and Sedentary Habits Among Adolescents with PCOS. https://www.jpagonline.org/article/S1083-3188(11)00466-9/abstract ↩︎
  3. Wright C E, et al. (2004). Dietary intake, physical activity, and obesity in women with polycystic ovary syndrome. https://www.nature.com/articles/0802661 ↩︎
  4. Thomson R L, et al. (2010). Lifestyle management improves quality of life and depression in overweight and obese women with polycystic ovary syndrome. https://www.fertstert.org/article/S0015-0282(09)03980-6/fulltext ↩︎
  5. Teede H J, et al. (2023). Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. https://academic.oup.com/humrep/article/38/9/1655/7241786 ↩︎
  6. Jurczewska J, et al. (2023). Physical Activity, Rather Than Diet, Is Linked to Lower Insulin Resistance in PCOS Women—A Case-Control Study. https://www.mdpi.com/2072-6643/15/9/2111 ↩︎
  7. Babaei Bonab S and Parvaneh M, (2023). Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19. https://www.sciencedirect.com/science/article/pii/S0765159723000758 ↩︎
  8. Weng Y, et al.(2023). Exercise-induced irisin improves follicular dysfunction by inhibiting IRE1α-TXNIP/ROS-NLRP3 pathway in PCOS. https://ovarianresearch.biomedcentral.com/articles/10.1186/s13048-023-01242-x ↩︎
  9. Rao M, et al. (2022). Effects of high-intensity interval training and strength training on levels of testosterone and physical activity among women with polycystic ovary syndrome. https://ogscience.org/journal/view.php?doi=10.5468/ogs.22002 ↩︎
  10. Almenning I, et al. (2015). Effects of High Intensity Interval Training and Strength Training on Metabolic, Cardiovascular and Hormonal Outcomes in Women with Polycystic Ovary Syndrome: A Pilot Study. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0138793 ↩︎
  11. Benham J L, et al. (2021). Exercise training and reproductive outcomes in women with polycystic ovary syndrome: A pilot randomized controlled trial. https://onlinelibrary.wiley.com/doi/10.1111/cen.14452 ↩︎
  12. Patten R K, et al. (2022). High-intensity training elicits greater improvements in cardio-metabolic and reproductive outcomes than moderate-intensity training in women with polycystic ovary syndrome: a randomized clinical trial. https://academic.oup.com/humrep/article/37/5/1018/6552984 ↩︎
  13. Lionett S, et al. (2021). Absent Exercise-Induced Improvements in Fat Oxidation in Women With Polycystic Ovary Syndrome After High-Intensity Interval Training. https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2021.649794/full ↩︎
  14. Mohammadi S, et al. (2023). Effects of eight-week high-intensity interval training on some metabolic, hormonal and cardiovascular indices in women with PCOS: a randomized controlled trail. https://bmcsportsscimedrehabil.biomedcentral.com/articles/10.1186/s13102-023-00653-z ↩︎
  15. Mei S, et al. (2022). Mediterranean Diet Combined With a Low-Carbohydrate Dietary Pattern in the Treatment of Overweight Polycystic Ovary Syndrome Patients. https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2022.876620/full ↩︎
  16. González F, et al. (2020). Inflammation Triggered by Saturated Fat Ingestion Is Linked to Insulin Resistance and Hyperandrogenism in Polycystic Ovary Syndrome. https://academic.oup.com/jcem/article/105/6/e2152/5788228 ↩︎
  17. Wang Q, et al. (2022). Higher dietary inflammation potential and certain dietary patterns are associated with polycystic ovary syndrome risk in China: A case-control study. https://www.sciencedirect.com/science/article/abs/pii/S027153172200001X ↩︎
  18. Sharkesh E Z, et al. (2021). The dietary inflammatory index is directly associated with polycystic ovary syndrome: A case-control study. https://onlinelibrary.wiley.com/doi/10.1111/cen.14672 ↩︎
  19. Shivappa N, et al. (2014). Designing and developing a literature-derived, population-based dietary inflammatory index. https://www.cambridge.org/core/journals/public-health-nutrition/article/designing-and-developing-a-literaturederived-populationbased-dietary-inflammatory-index/30BE2C2295CE93DC6B54F9F9AD50CC68 ↩︎
  20. Łagowska K and Pieczyńska J M, (2022). Not only diet quality and physical activity but also snacking and skipping meals could be related with menstrual disorders in PCOS. https://www.tandfonline.com/doi/full/10.1080/03630242.2022.2106529 ↩︎
  21. Jakubowicz D, et al. (2013). Effects of caloric intake timing on insulin resistance and hyperandrogenism in lean women with polycystic ovary syndrome. https://portlandpress.com/clinsci/article-abstract/125/9/423/69160/Effects-of-caloric-intake-timing-on-insulin ↩︎
  22. Papakonstantinou E, et al. (2016). Effect of meal frequency on glucose and insulin levels in women with polycystic ovary syndrome: a randomised trial. https://www.nature.com/articles/ejcn2015225 ↩︎
  23. Kiddy D S, et al. (1992). Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2265.1992.tb02909.x ↩︎
  24. Li C, et al. (2021). Eight-hour time-restricted feeding improves endocrine and metabolic profiles in women with anovulatory polycystic ovary syndrome. https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-021-02817-2 ↩︎
  25. Talebi S, et al. (2024). The effects of time-restricted eating alone or in combination with probiotic supplementation in comparison with a calorie-restricted diet on endocrine and metabolic profiles in women with polycystic ovary syndrome: A randomized clinical trial. https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/dom.15801 ↩︎
  26. Feyzioglu B S, et al. (2023). Eight-Hour Time-Restricted Feeding: A Strong Candidate Diet Protocol for First-Line Therapy in Polycystic Ovary Syndrome. https://www.mdpi.com/2072-6643/15/10/2260 ↩︎
  27. Mohammadi S, et al. (2023). Effects of eight-week high-intensity interval training on some metabolic, hormonal and cardiovascular indices in women with PCOS: a randomized controlled trail. https://bmcsportsscimedrehabil.biomedcentral.com/articles/10.1186/s13102-023-00653-z ↩︎
  28. Jiskoot G, et al. (2022). Lifestyle treatment in women with polycystic ovary syndrome: predictors of weight loss and dropout. https://onlinelibrary.wiley.com/doi/10.1002/brb3.2621 ↩︎
  29. Hager M, et al. (2023). Stress and polycystic ovarian morphology in functional hypothalamic amenorrhea: a retrospective cohort study. https://rbej.biomedcentral.com/articles/10.1186/s12958-023-01095-5 ↩︎
  30. Lennartsson A K, et al. (2012). DHEA and DHEA-S response to acute psychosocial stress in healthy men and women. https://pubmed.ncbi.nlm.nih.gov/22445967/ ↩︎
  31. Carmina E and Longo R A, (2022). Increased Prevalence of Elevated DHEAS in PCOS Women with Non-Classic (B or C) Phenotypes: A Retrospective Analysis in Patients Aged 20 to 29 Years. https://www.mdpi.com/2073-4409/11/20/3255 ↩︎
  32. Medeiros S F, et al. (2022). Adrenal Androgen Predictive Effects on Clinical and Metabolic Abnormalities of Polycystic Ovary Syndrome. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9948267/ ↩︎
  33. Khan S H, et al. (2021). Dehydroepiandrosterone Sulfate (DHEAS) Levels in Polycystic Ovarian Syndrome (PCOS). https://jcpsp.pk/article-detail/dehydroepiandrosterone-sulfate-(dheas)-levels-in-polycystic-ovarian-syndrome-(pcos) ↩︎
  34. Marschalek M L, et al. (2023). A case-control study about markers of stress in normal-/overweight women with polycystic ovary syndrome and in controls. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2023.1173422/full ↩︎
  35. Dumesic D A, et al. (2023). Interplay of Cortisol, Testosterone, and Abdominal Fat Mass in Normal-weight Women With Polycystic Ovary Syndrome. https://academic.oup.com/jes/article/7/8/bvad079/7191792 ↩︎
  36. Cohen S, et al. (1983). Perceived Stress Scale. https://psycnet.apa.org/doiLanding?doi=10.1037/t02889-000 ↩︎
  37. Majewska J, et al. (2023). Bisphenol A analogues and metabolic syndrome in women with polycystic ovary syndrome. https://www.sciencedirect.com/science/article/pii/S0890623823001855 ↩︎
  38. Patel J, et al. (2024). Connecting Bisphenol A Exposure to PCOS: Findings from a Case-Control Investigation. https://link.springer.com/article/10.1007/s43032-024-01548-1 ↩︎
  39. Jurewicz J, et al. (2020). Serum bisphenol A analogues in women diagnosed with the polycystic ovary syndrome – is there an association? https://www.sciencedirect.com/science/article/pii/S0269749120366513 ↩︎
  40. Rochester J R and Bolden A L, (2015). Bisphenol S and F: A Systematic Review and Comparison of the Hormonal Activity of Bisphenol A Substitutes. https://ehp.niehs.nih.gov/doi/10.1289/ehp.1408989 ↩︎
  41. Yang Q, et al. (2015). Association of serum levels of typical organic pollutants with polycystic ovary syndrome (PCOS): a case–control study. https://academic.oup.com/humrep/article/30/8/1964/950085 ↩︎
  42. Vagi S J, et al. (2014). Exploring the potential association between brominated diphenyl ethers, polychlorinated biphenyls, organochlorine pesticides, perfluorinated compounds, phthalates, and bisphenol a in polycystic ovary syndrome: a case–control study. https://bmcendocrdisord.biomedcentral.com/articles/10.1186/1472-6823-14-86 ↩︎
  43. Li J, et al. (2018). Effect of exposure to second-hand smoke from husbands on biochemical hyperandrogenism, metabolic syndrome and conception rates in women with polycystic ovary syndrome undergoing ovulation induction. https://academic.oup.com/humrep/article/33/4/617/4877148 ↩︎
  44. Xirofotos D, et al. (2016). The amount and duration of smoking is associated with aggravation of hormone and biochemical profile in women with PCOS. https://www.tandfonline.com/doi/full/10.3109/09513590.2015.1101440 ↩︎
  45. Cupisti S, et al. (2009). Smoking is associated with increased free testosterone and fasting insulin levels in women with polycystic ovary syndrome, resulting in aggravated insulin resistance. https://www.fertstert.org/article/S0015-0282(09)00632-3/fulltext ↩︎
  46. Zhan W, et al. (2023). Environmental Exposure to Emerging Alternatives of Per- and Polyfluoroalkyl Substances and Polycystic Ovarian Syndrome in Women Diagnosed with Infertility: A Mixture Analysis. https://ehp.niehs.nih.gov/doi/10.1289/EHP11814 ↩︎
  47. Hammarstrand S, et al. (2021). Perfluoroalkyl substances (PFAS) in drinking water and risk for polycystic ovarian syndrome, uterine leiomyoma, and endometriosis: A Swedish cohort study. https://www.sciencedirect.com/science/article/pii/S016041202100444X ↩︎
  48. Fenkci S M, et al. (2008). Serum total L-carnitine levels in non-obese women with polycystic ovary syndrome. https://academic.oup.com/humrep/article/23/7/1602/735997 ↩︎
  49. Tauqir S, et al. (2021). Acetyl-L-Carnitine Ameliorates Metabolic and Endocrine Alterations in Women with PCOS: A Double-Blind Randomized Clinical Trial. https://link.springer.com/article/10.1007/s12325-021-01789-5 ↩︎
  50. Salehpour S, et al. (2019). Effects of L-carnitine on Polycystic Ovary Syndrome. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6798588/ ↩︎
  51. Di Nicuolo F, et al. (2021). α-Lipoic Acid and its Role on Female Reproduction. https://www.eurekaselect.com/article/118608 ↩︎
  52. Scarinci E, et al. (2021). Insulin-sensitizing effect and antioxidant action of alpha lipoic acid in oligomenorrheic women with polycystic ovary syndrome. https://www.minervamedica.it/en/journals/minerva-obstetrics-gynecology/article.php?cod=R09Y2023N02A0165 ↩︎
  53. Pei Y, et al. (2023). Beneficial effects of pioglitazone and α-lipoic acid in patients with polycystic ovaries syndrome. https://www.europeanreview.org/article/33285 ↩︎
  54. Genazzani A D, et al. (2024). Alpha lipoic acid administration improved both peripheral sensitivity to insulin and liver clearance of insulin reducing potential risk of diabetes and nonalcoholic fatty liver disease in overweight/obese PCOS patients. https://www.tandfonline.com/doi/full/10.1080/09513590.2024.2341701 ↩︎
  55. Fruzzetti F, et al. (2019). Long-term treatment with α-lipoic acid and myo-inositol positively affects clinical and metabolic features of polycystic ovary syndrome. https://www.tandfonline.com/doi/full/10.1080/09513590.2019.1640673 ↩︎
  56. De Cicco S, et al. (2017). Myoinositol combined with alpha-lipoic acid may improve the clinical and endocrine features of polycystic ovary syndrome through an insulin-independent action. https://www.tandfonline.com/doi/full/10.1080/09513590.2017.1313972 ↩︎
  57. Torge N, et al. (2017). Polycystic Ovary Syndrome in Adolescence: new therapeutic approach with Inositol and Alpha-Lipoic Acid. https://www.postersessiononline.eu/173580348_eu/congresos/55ESPE/aula/-P1_336_55ESPE.pdf ↩︎
  58. Genazzani A D, et al. (2019). Differential insulin response to oral glucose tolerance test (OGTT) in overweight/obese polycystic ovary syndrome patients undergoing to myo-inositol (MYO), alpha lipoic acid (ALA), or combination of both. https://www.tandfonline.com/doi/full/10.1080/09513590.2019.1640200 ↩︎
  59. Karamali M and Gholizadeh M, (2021). The effects of coenzyme Q10 supplementation on metabolic profiles and parameters of mental health in women with polycystic ovary syndrome. https://www.tandfonline.com/doi/full/10.1080/09513590.2021.1991910 ↩︎
  60. Ahmadi Asouri S, et al. (2024). The effect of coenzyme Q10 intake on metabolic profiles in women candidates for in-vitro fertilization: a randomised trial. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11152844/ ↩︎
  61. Galano A, et al. (2011). Melatonin as a natural ally against oxidative stress: a physicochemical examination. https://onlinelibrary.wiley.com/doi/10.1111/j.1600-079X.2011.00916.x ↩︎
  62. Xie F, et al. (2021). Melatonin ameliorates ovarian dysfunction by regulating autophagy in PCOS via the PI3K-Akt pathway. https://rep.bioscientifica.com/view/journals/rep/162/1/REP-20-0643.xml ↩︎
  63. Tanavde V and Maitra A, (2011). In Vitro Modulation of Steroidogenesis and Gene Expression by Melatonin: A Study with Porcine Antral Follicles. https://www.tandfonline.com/doi/full/10.1081/ERC-120026946 ↩︎
  64. Jamilian M, et al. (2019). Effects of Melatonin Supplementation on Hormonal, Inflammatory, Genetic, and Oxidative Stress Parameters in Women With Polycystic Ovary Syndrome. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2019.00273/full ↩︎
  65. Tagliaferri V, et al. (2017). Melatonin Treatment May Be Able to Restore Menstrual Cyclicity in Women With PCOS: A Pilot Study. https://link.springer.com/article/10.1177/1933719117711262 ↩︎
  66. Luo Xi, et al. (2021). Associations of Serum Magnesium With Insulin Resistance and Testosterone in Women With Polycystic Ovary Syndrome. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2021.683040/full ↩︎
  67. Szczuko M, et al. (2016). Quantitative assessment of nutrition in patients with polycystic ovary syndrome (PCOS). https://pubmed.ncbi.nlm.nih.gov/27925712/ ↩︎
  68. Gholizadeh-Moghaddam M, et al. (2022). Effect of magnesium supplementation in improving hyperandrogenism, hirsutism, and sleep quality in women with polycystic ovary syndrome: A randomized, placebo-controlled clinical trial. https://onlinelibrary.wiley.com/doi/10.1002/hsr2.1013 ↩︎
  69. Hamilton K P, et al. (2019). Insulin Resistance and Serum Magnesium Concentrations among Women with Polycystic Ovary Syndrome. https://cdn.nutrition.org/article/S2475-2991(22)13080-5/fulltext ↩︎
  70. Alizadeh M, et al. (2021). Metabolic and hormonal effects of melatonin and/or magnesium supplementation in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. https://nutritionandmetabolism.biomedcentral.com/articles/10.1186/s12986-021-00586-9 ↩︎
  71. Mousavi R, et al. (2021). Effects of Melatonin and/or Magnesium Supplementation on Biomarkers of Inflammation and Oxidative Stress in Women with Polycystic Ovary Syndrome: a Randomized, Double-Blind, Placebo-Controlled Trial. https://link.springer.com/article/10.1007/s12011-021-02725-y ↩︎
  72. Khademi Z, et al. (2023). Association Between Selenium and Circulating Adipokine Levels in Patients with Polycystic Ovary Syndrome. https://link.springer.com/article/10.1007/s12011-023-03935-2 ↩︎
  73. Amirkhizi F, et al. (2023). Association of Serum Selenium and Selenoprotein P with Oxidative Stress Biomarkers in Patients with Polycystic Ovary Syndrome. https://link.springer.com/article/10.1007/s12011-023-03747-4 ↩︎
  74. Coskun A, et al. (2013). Plasma selenium levels in Turkish women with polycystic ovary syndrome. https://www.ejog.org/article/S0301-2115(13)00064-X/abstract ↩︎
  75. Razavi M, et al. (2016). Selenium Supplementation and the Effects on Reproductive Outcomes, Biomarkers of Inflammation, and Oxidative Stress in Women with Polycystic Ovary Syndrome. https://www.thieme-connect.de/products/ejournals/abstract/10.1055/s-0035-1559604 ↩︎
  76. Modarres S Z, et al. (2022). The effects of selenium supplementation on glycemic control, serum lipoproteins and biomarkers of oxidative stress in infertile women diagnosed with polycystic ovary syndrome undergoing in vitro fertilization: A randomized, double-blind, placebo-controlled trial. https://clinicalnutritionespen.com/article/S2405-4577(22)00426-0/abstract ↩︎
  77. Kazemi M, et al. (2021). Randomized double blind clinical trial evaluating the Ellagic acid effects on insulin resistance, oxidative stress and sex hormones levels in women with polycystic ovarian syndrome. https://ovarianresearch.biomedcentral.com/articles/10.1186/s13048-021-00849-2 ↩︎
  78. Khang I, et al. (2016). Improvements in Metabolic Health with Consumption of Ellagic Acid and Subsequent Conversion into Urolithins: Evidence and Mechanisms. https://www.sciencedirect.com/science/article/pii/S2161831322007827 ↩︎
  79. Abedini M, et al. (2023). The effect of concentrated pomegranate juice on biomarkers of inflammation, oxidative stress, and sex hormones in overweight and obese women with polycystic ovary syndrome: A randomized controlled trial. https://onlinelibrary.wiley.com/doi/10.1002/ptr.7731 ↩︎
  80. Talebi S, et al. (2023). The effects of pro-, pre-, and synbiotics supplementation on polycystic ovary syndrome: an umbrella review of meta-analyses of randomized controlled trials. https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2023.1178842/full ↩︎
  81. Darvishi S, et al. (2021). Synbiotic Supplementation Improves Metabolic Factors and Obesity Values in Women with Polycystic Ovary Syndrome Independent of Affecting Apelin Levels: A Randomized Double-Blind Placebo – Controlled Clinical Trial. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7838763/ ↩︎
  82. Esmaeilinezhad Z, et al. (2019). Effect of synbiotic pomegranate juice on glycemic, sex hormone profile and anthropometric indices in PCOS: A randomized, triple blind, controlled trial. https://www.nmcd-journal.com/article/S0939-4753(18)30227-8/abstract ↩︎
  83. Montelius C, et al. (2014). Body weight loss, reduced urge for palatable food and increased release of GLP-1 through daily supplementation with green-plant membranes for three months in overweight women. https://www.sciencedirect.com/science/article/pii/S0195666314003493 ↩︎
  84. Nikrad N, et al. (2023). The effect of calorie-restriction along with thylakoid membranes of spinach on the gut-brain Axis Pathway and oxidative stress biomarkers in obese women with polycystic ovary syndrome: a Randomized, Double-blind, placebo-controlled clinical trial. https://ovarianresearch.biomedcentral.com/articles/10.1186/s13048-023-01288-x ↩︎
  85. Tabrizi F P F, et al. (2020). The effects of spinach-derived thylakoid supplementation in combination with calorie restriction on anthropometric parameters and metabolic profiles in obese women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled clinical trial. https://nutritionj.biomedcentral.com/articles/10.1186/s12937-020-00601-4 ↩︎
  86. Kazerooni T, et al. (2008). Effect of folic acid in women with and without insulin resistance who have hyperhomocysteinemic polycystic ovary syndrome. https://obgyn.onlinelibrary.wiley.com/doi/10.1016/j.ijgo.2007.10.024 ↩︎
  87. Guzelmeric K, et al. (2007). Chronic inflammation and elevated homocysteine levels are associated with increased body mass index in women with polycystic ovary syndrome. https://www.tandfonline.com/doi/full/10.1080/09513590701554306 ↩︎
  88. Ganie M A, et al. (2024). Impact of Prevalent Dietary Pattern on Serum Vitamin B12 Status and Its Association With Inflammation Among Reproductive Age Women. https://onlinelibrary.wiley.com/doi/10.1002/mnfr.202300315 ↩︎
  89. Kaye A, et al. (2020). Folic Acid Supplementation in Patients with Elevated Homocysteine Levels. https://link.springer.com/article/10.1007/s12325-020-01474-z ↩︎
  90. Schiuma N, et al. (2019). Micronutrients in support to the one carbon cycle for the modulation of blood fasting homocysteine in PCOS women. https://link.springer.com/article/10.1007/s40618-019-01163-x ↩︎
  91. Tsuji A, et al. (2017). Effects of Mild and Severe Vitamin B1 Deficiencies on the Meiotic Maturation of Mice Oocytes. https://journals.sagepub.com/doi/10.1177/1178638817693824 ↩︎
  92. Szczuko M, et al. (2021). A Properly Balanced Reduction Diet and/or Supplementation Solve the Problem with the Deficiency of These Vitamins Soluble in Water in Patients with PCOS. https://www.mdpi.com/2072-6643/13/3/746 ↩︎
  93. Moti M, et al. (2024). The Effects of Thiamine Supplementation on General Health and Infertility Treatment Outcomes in Women with Polycystic Ovary Syndrome: A Triple-Blinded Randomized Placebo-Controlled Clinical Trial. https://www.ijfs.ir/article_706404.html ↩︎
  94. Bourron O and Phan F, (2019). Vitamin K: a nutrient which plays a little-known role in glucose metabolism. https://journals.lww.com/co-clinicalnutrition/abstract/2019/03000/vitamin_k__a_nutrient_which_plays_a_little_known.15.aspx ↩︎
  95. Tarkesh F, et al. (2022). Effect of vitamin K2 administration on depression status in patients with polycystic ovary syndrome: a randomized clinical trial. https://bmcwomenshealth.biomedcentral.com/articles/10.1186/s12905-022-01825-8 ↩︎
  96. Tarkesh F, et al. (2020). Beneficial health effects of Menaquinone-7 on body composition, glycemic indices, lipid profile, and endocrine markers in polycystic ovary syndrome patients. https://onlinelibrary.wiley.com/doi/10.1002/fsn3.1837 ↩︎
  97. Drincic A T, et al. (2012). Volumetric Dilution, Rather Than Sequestration Best Explains the Low Vitamin D Status of Obesity. https://onlinelibrary.wiley.com/doi/10.1038/oby.2011.404 ↩︎
  98. Uwitonze A M and Razzaque M S, (2018). Role of Magnesium in Vitamin D Activation and Function. https://www.degruyter.com/document/doi/10.7556/jaoa.2018.037/html ↩︎
  99. Simpson S, et al. (2020). The association between anti-Müllerian hormone and vitamin 25(OH)D serum levels and polycystic ovarian syndrome in adolescent females. https://rbej.biomedcentral.com/articles/10.1186/s12958-020-00676-y ↩︎
  100. Jafari-Sfidvajani S, et al. (2018). The effect of vitamin D supplementation in combination with low-calorie diet on anthropometric indices and androgen hormones in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial. https://link.springer.com/article/10.1007/s40618-017-0785-9 ↩︎
  101. Al-Bayyari N, et al. (2020). Androgens and hirsutism score of overweight women with polycystic ovary syndrome improved after vitamin D treatment: A randomized placebo controlled clinical trial. https://www.clinicalnutritionjournal.com/article/S0261-5614(20)30496-9/abstract ↩︎
  102. Lerchbaum E, et al. (2021). Effects of Vitamin D Supplementation on Surrogate Markers of Fertility in PCOS Women: A Randomized Controlled Trial. https://www.mdpi.com/2072-6643/13/2/547 ↩︎
  103. Ağar M, et al. (2022). Vitamin D supplementation inhibits NF-kß signaling pathway in lean and obese women with PCOS. https://www.europeanreview.org/article/28967 ↩︎
  104. Thys-Jacobs S, et al. (1999). Vitamin D and calcium dysregulation in the polycystic ovarian syndrome. https://www.sciencedirect.com/science/article/pii/S0039128X99000124 ↩︎
  105. Kadoura S, et al. (2019). Effect of Calcium and Vitamin D Supplements as an Adjuvant Therapy to Metformin on Menstrual Cycle Abnormalities, Hormonal Profile, and IGF-1 System in Polycystic Ovary Syndrome Patients: A Randomized, Placebo-Controlled Clinical Trial. https://onlinelibrary.wiley.com/doi/10.1155/2019/9680390 ↩︎
  106. Sert Z S, et al. (2022). Effect of calcium and vitamin D supplementation on the clinical, hormonal, and metabolic profile in non-obese women with polycystic ovary syndrome. https://link.springer.com/article/10.1007/s11845-021-02899-3 ↩︎
  107. Unfer V, et al. (2020). Altered Ovarian Inositol Ratios May Account for Pathological Steroidogenesis in PCOS. https://www.mdpi.com/1422-0067/21/19/7157 ↩︎
  108. Fedeli V, et al. (2023). The Role of Inositols in the Hyperandrogenic Phenotypes of PCOS: A Re-Reading of Larner’s Results. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10093919/ ↩︎
  109. Cianci A and Vitale S G, (2022). D-Chiro-inositol and PCOS: between myth and reality. The never-ending story. https://www.tandfonline.com/doi/full/10.1080/09637486.2022.2029830 ↩︎
  110. Facchinetti F, et al. (2019). Short-term effects of metformin and myo-inositol in women with polycystic ovarian syndrome (PCOS): a meta-analysis of randomized clinical trials. https://www.tandfonline.com/doi/full/10.1080/09513590.2018.1540578 ↩︎
  111. Pizzo A, et al. (2013). Comparison between effects of myo-inositol and d-chiro-inositol on ovarian function and metabolic factors in women with PCOS. https://www.tandfonline.com/doi/full/10.3109/09513590.2013.860120 ↩︎
  112. Constantino D, et al. (2009). Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial. https://pubmed.ncbi.nlm.nih.gov/19499845/ ↩︎
  113. Unfer V, et al. (2023). Treatment with Myo-Inositol Does Not Improve the Clinical Features in All PCOS Phenotypes. https://www.mdpi.com/2227-9059/11/6/1759 ↩︎
  114. Kamenov Z, et al. (2023). Comparing the Efficacy of Myo-Inositol Plus α-Lactalbumin vs. Myo-Inositol Alone on Reproductive and Metabolic Disturbances of Polycystic Ovary Syndrome. https://www.mdpi.com/2218-1989/13/6/717 ↩︎
  115. Hernandez Marin I, et al. (2021). A multicenter clinical study with myo-inositol and alpha-lactalbumin in Mexican and Italian PCOS patients. https://www.europeanreview.org/article/25743 ↩︎
  116. Fruzzetti F, et al. (2019). Long-term treatment with α-lipoic acid and myo-inositol positively affects clinical and metabolic features of polycystic ovary syndrome. https://www.tandfonline.com/doi/full/10.1080/09513590.2019.1640673 ↩︎
  117. Genazzani A D, et al. (2019). Differential insulin response to oral glucose tolerance test (OGTT) in overweight/obese polycystic ovary syndrome patients undergoing to myo-inositol (MYO), alpha lipoic acid (ALA), or combination of both. https://www.tandfonline.com/doi/full/10.1080/09513590.2019.1640200 ↩︎
  118. Monastra G, et al. (2018). Alpha-lactalbumin Effect on Myo-inositol Intestinal Absorption: In vivo and In vitro. https://www.eurekaselect.com/article/90292. ↩︎
  119. Oliva M M, et al. (2018). Effects of myo-inositol plus alpha-lactalbumin in myo-inositol-resistant PCOS women. https://ovarianresearch.biomedcentral.com/articles/10.1186/s13048-018-0411-2 ↩︎
  120. Alessandri G, et al. (2024). Disclosing α-lactalbumin impact on the intestinal and vaginal microbiota of women suffering from polycystic ovary syndrome. https://enviromicro-journals.onlinelibrary.wiley.com/doi/10.1111/1751-7915.14540 ↩︎
  121. De Grazia S, et al. (2012). Myo-inositol soft gel capsules may prevent the risk of coffee-induced neural tube defects. https://www.tandfonline.com/doi/full/10.1517/17425247.2012.701616 ↩︎
  122. Benvenga S, (2012). (Soft) capsules of wisdom: preventing myo-inositol malabsorption caused by coffee. https://www.tandfonline.com/doi/full/10.1517/17425247.2012.719495 ↩︎
  123. Mishra N, et al. (2022). Study on the Effect of Berberine, Myoinositol, and Metformin in Women with Polycystic Ovary Syndrome: A Prospective Randomised Study. https://www.cureus.com/articles/77796-study-on-the-effect-of-berberine-myoinositol-and-metformin-in-women-with-polycystic-ovary-syndrome-a-prospective-randomised-study#!/ ↩︎
  124. Wei W, et al. (2011). A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. https://academic.oup.com/ejendo/article-abstract/166/1/99/6659259 ↩︎
  125. Orio F, et al. (2013). Berberine improves reproductive features in obese Caucasian women with polycystic ovary syndrome independently of changes of insulin sensitivity. https://www.sciencedirect.com/science/article/pii/S2212826313000742 ↩︎
  126. Di Perro F, et al. (2023). Effect of Berberine Phytosome on reproductive, dermatologic, and metabolic characteristics in women with polycystic ovary syndrome: a controlled, randomized, multi-centric, open-label clinical trial. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1269605/full ↩︎
  127. Rondanelli M, et al. (2021). Berberine Phospholipid Is an Effective Insulin Sensitizer and Improves Metabolic and Hormonal Disorders in Women with Polycystic Ovary Syndrome: A One-Group Pretest–Post-Test Explanatory Study. https://www.mdpi.com/2072-6643/13/10/3665 ↩︎
  128. Petrangolini G, et al. (2021). Development of an Innovative Berberine Food-Grade Formulation with an Ameliorated Absorption: In Vitro Evidence Confirmed by Healthy Human Volunteers Pharmacokinetic Study. https://onlinelibrary.wiley.com/doi/10.1155/2021/7563889 ↩︎
  129. Duong T T, et al. (2021). Nanoformulation and Evaluation of Oral Berberine-Loaded Liposomes. https://www.mdpi.com/1420-3049/26/9/2591 ↩︎
  130. Moreira E S, et al. (2022). The short-term effects of berberine in the liver: Narrow margins between benefits and toxicity. https://www.sciencedirect.com/science/article/pii/S0378427422009845 ↩︎
  131. Rondanelli M, et al. (2014). Focus on metabolic and nutritional correlates of polycystic ovary syndrome and update on nutritional management of these critical phenomena. https://link.springer.com/article/10.1007/s00404-014-3433-z ↩︎
  132. Nadjarzadeh A, et al. (2013). The effect of omega-3 supplementation on androgen profile and menstrual status in women with polycystic ovary syndrome: A randomized clinical trial. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3941370/ ↩︎
  133. Bahramian H, et al. (2023). Effects of single-dose and co-supplementation of vitamin D and omega-3 on metabolic profile in women with polycystic ovary syndrome: An RCT. https://knepublishing.com/index.php/ijrm/article/view/13889 ↩︎
  134. Khani B, et al. (2017). Omega-3 supplementation effects on polycystic ovary syndrome symptoms and metabolic syndrome. https://journals.lww.com/jrms/fulltext/2017/22000/omega_3_supplementation_effects_on_polycystic.64.aspx ↩︎
  135. Shah M, et al. (2023). Effect of quercetin on steroidogenesis and folliculogenesis in ovary of mice with experimentally-induced polycystic ovarian syndrome. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2023.1153289/full ↩︎
  136. Rezvan N, et al. (2018). Oral Quercetin Supplementation Enhances Adiponectin Receptor Transcript Expression in Polycystic Ovary Syndrome Patients: A Randomized Placebo-Controlled Double-Blind Clinical Trial. https://www.celljournal.org/article_250471.html ↩︎
  137. Rezvan N, et al. (2017). Effects of Quercetin on Adiponectin-Mediated Insulin Sensitivity in Polycystic Ovary Syndrome: A Randomized Placebo-Controlled Double-Blind Clinical Trial. https://www.thieme-connect.de/products/ejournals/abstract/10.1055/s-0042-118705 ↩︎
  138. Vaez S, et al. (2022). Quercetin and polycystic ovary syndrome; inflammation, hormonal parameters and pregnancy outcome: A randomized clinical trial. https://onlinelibrary.wiley.com/doi/10.1111/aji.13644 ↩︎
  139. Shen W, et al. (2021). Effects of Tea Consumption on Anthropometric Parameters, Metabolic Indexes and Hormone Levels of Women with Polycystic Ovarian Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2021.736867/full ↩︎
  140. Mombaini E, et al. (2017). The Impact of Green Tea Supplementation on Anthropometric Indices and Inflammatory Cytokines in Women with Polycystic Ovary Syndrome. https://onlinelibrary.wiley.com/doi/abs/10.1002/ptr.5795 ↩︎
  141. Grant P, (2009). Spearmint herbal tea has significant anti-androgen effects in polycystic ovarian syndrome. a randomized controlled trial. https://onlinelibrary.wiley.com/doi/10.1002/ptr.2900 ↩︎
  142. Akdoğan M, et al. (2007). Effect of spearmint (Mentha spicata Labiatae) teas on androgen levels in women with hirsutism. https://onlinelibrary.wiley.com/doi/10.1002/ptr.2074 ↩︎
  143. Bethseda, (2012). LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. https://www.ncbi.nlm.nih.gov/books/NBK547925/ ↩︎
  144. Fuzi S, et al. (2017). A 1-h time interval between a meal containing iron and consumption of tea attenuates the inhibitory effects on iron absorption: a controlled trial in a cohort of healthy UK women using a stable iron isotope. https://www.sciencedirect.com/science/article/pii/S0002916522026983 ↩︎
  145. Hu J, et al. (2018). The safety of green tea and green tea extract consumption in adults – Results of a systematic review. https://www.sciencedirect.com/science/article/pii/S0273230018300928 ↩︎
  146. Ghanbarzadeh-Ghashti N, et al. (2023). The effect of Curcumin on metabolic parameters and androgen level in women with polycystic ovary syndrome: a randomized controlled trial. https://bmcendocrdisord.biomedcentral.com/articles/10.1186/s12902-023-01295-5 ↩︎
  147. Sohaei S, et al. (2019). The effects of curcumin supplementation on glycemic status, lipid profile and hs-CRP levels in overweight/obese women with polycystic ovary syndrome: A randomized, double-blind, placebo-controlled clinical trial. https://www.sciencedirect.com/science/article/pii/S0965229919308660 ↩︎
  148. Sohrevardi S M, et al. (2021). Therapeutic Effect of Curcumin in Women with Polycystic Ovary Syndrome Receiving Metformin: A Randomized Controlled Trial. https://link.springer.com/chapter/10.1007/978-3-030-64872-5_9 ↩︎

Share this post

Share on LinkedIn Share on Pinterest

fertilPEDIA

Questions or comments?